Biocause Pharma(SZ:000627) Zhi Tong Cai Jing·2025-08-31 08:24Core Viewpoint - *ST Tianmao (000627) is undergoing a significant business restructuring, leading to major uncertainties that may substantially impact Tianmao Group [1] Group 1: Business Restructuring - The company plans to withdraw its A-share listing on the Shenzhen Stock Exchange through a shareholder resolution, which will result in the stock being transferred to the delisting segment managed by the National Small and Medium Enterprises Share Transfer System [1] - The company will initiate a protection mechanism for dissenting shareholders and other shareholders, providing cash options to all A-share shareholders registered on the cash option equity registration date, excluding certain parties [1] Group 2: Stock Suspension and Delisting - The company's stock has been suspended from trading since August 14, 2025, and the decision to terminate the listing has been approved in the first extraordinary general meeting of shareholders in 2025 [1] - Following the shareholder resolution to terminate the listing, the company will submit an application for voluntary delisting to the Shenzhen Stock Exchange within fifteen trading days [1]